Lupin Launches Fixed-Dose Triple Combination Inhaler for COPD in India

Lupin launches fixed-dose triple combination inhaler for COPD in India

According to the company, the therapy aims to serve more than 55 million people living with COPD in India, where the condition remains a leading cause of death and disability.

Lupin Launches Triple-Combination COPD Inhaler in India

Shares of Lupin Ltd were trading in the green and 1% higher on 6 October after the pharmaceutical company launched Formoflo-G MDI, a new triple-combination inhaler for chronic obstructive pulmonary disease (COPD) in India.  The launch follows approval from the Drug Controller General of India (DCGI) and adds another differentiated...

Lupin inches up on launching world’s first triple combination drug ‘Formoflo-G MDI’ for COPD in India

Mumbai, October 6 (Udaipur Kiran): Lupin is currently trading at Rs. 2015.60, up by 5.60 points or 0.28% from its previous closing of Rs. 2010.00 on the BSE. The scrip opened at Rs. 2026.75 and has touched a high and low of Rs. 2026.75 and Rs. 2004.65 respectively. So far 3733 shares were traded on ... Lupin inches up on launching world’s first triple combination drug ‘Formoflo-G MDI’ for COPD in India

Lupin launches triple-combination MDI for COPD in India

Lupin has launched Formoflo-G MDI, the world’s first fixed-dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India, following approval from the Drug Controller General of India (DCGI). Lupin Formoflo-G is a first-of-its-kind MDI that combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management and treatment of moderate to severe COPD. The product…